

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Attorney Docket No. 056291-5174-US		Application No. 10/505,231	
PTO Form 1449 August 4, 2006				Applicants: GELLERT et al.		Filing Date: August 19, 2004	
Group Art Unit: 1615							

U.S. PATENT DOCUMENTS

Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
JDA	1.	20050209229	September 22, 2005	Gilday et al.	514	234.2	May 23, 2005
JDA	2.	20020177601	November 28, 2002	Himmelsbach et al.	514	266.2	August 23, 2001
JDA	3.	5,610,193	March 11, 1997	Al-Razzak et al.	514	616	May 22, 1996
JDA	4.	4,178,376	December 11, 1979	Higuchi et al.	514	311	January 21, 1977
JDA	5.	3,608,063	September 21, 1971	Banker	424	485	August 15, 1969

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Sub-Class	Translation
JDA	6.	DE 3233764	May 7, 1987	Germany			Yes
	7.	EP 1027888	August 16, 2000	EPA			
	8.	EP 103387	March 21, 1984	EPA			
	9.	EP 640341	March 1, 1995	EPA			
	10.	GB 1278816	June 21, 1972	Great Britain			
	11.	JP 05-255066	October 5, 1993	Japan			Yes
	12.	JP 62-123117	June 4, 1987	Japan			Yes
	13.	WO 95/09614	April 13, 1995	WIPO			
	14.	WO 97/02017	January 23, 1997	WIPO			
	15.	WO 98/55148	December 10, 1998	WIPO			
	16.	WO 00/16776	March 30, 2000	WIPO			Yes
	17.	WO 00/55141	September 21, 2000	WIPO			
	18.	WO 00/56338	September 28, 2000	WIPO			
	19.	WO 02/06834	January 24, 2002	WIPO			
	20.	WO 02/64132	August 22, 2002	WIPO			
	21.	WO 02/65834	August 29, 2002	WIPO			
	22.	WO 03/017940	March 6, 2003	WIPO			
	23.	WO 03/024426	March 27, 2003	WIPO			
	24.	WO 03/024429	March 27, 2003	WIPO			
	25.	WO 03/024430	March 27, 2003	WIPO			
JDA	26.	WO 03/072139	September 4, 2003	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

JDA	27.	Baselga et al. "Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types" J Clin Oncol. 20(21): 4292-4302 (2002)
JDA	28.	Berger et al. "Supersaturation of sulfates in electrodialysis" Ind. Eng. Chem., Process Design Develop. 1: 229-236 (1962) Abstract
JDA	29.	Brewster et al. "A Novel Cyclodextrin-containing Glass Thermoplastic System (GTS) for Formulating Poorly Water Soluble Drug Candidates: Preclinical and Clinical Results" Journal of Inclusion Phenomena and Macrocyclic Chemistry 44(1-4): 35-38 (2002)

Examiner	/James Anderson/	Date Considered	02/20/2007
----------	------------------	-----------------	------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449 August 4, 2006				Attorney Docket No. 056291-5174-US		Application No. 10/505,231	
				Applicants: GELLERT <i>et al.</i>			
				Filing Date: August 19, 2004		Group Art Unit: 1615	

U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date

FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)			
JDA	30.	Capello et al. "Percutaneous penetration of Ibuprofen from supersaturated solutions" Acta Technologiae et Legis Medicamenti XIII(1): 25-35 (2002) (Translation enclosed)	
JDA	31.	Espinoza "Influence of admixed citric acid on the release profile of pelanserin hydrochloride from HPMC matrix tablets" Int J Pharm. 201(2):165-173 (2000)	
JDA	32.	McKillop et al. "Cytochrome P450-dependent metabolism of gefitinib" Xenobiotica 35(1): 39-50 (2005)	
JDA	33.	McKillop et al. "Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man" Xenobiotica 34(10): 917-934 (2004)	
JDA	34.	Munday "Film coated pellets containing verapamil hydrochloride: enhanced dissolution into neutral medium" Drug Development and Industrial Pharmacy 29(5): 575-583 (2003)	
JDA	35.	N Magné et al. "Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer" British Journal of Cancer 86: 819-827 (2002)	
JDA	36.	Nakagawa et al. "Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors" Ann Oncol. 14(6): 922-930 (2003)	
JDA	37.	Neiman et al. "Separation of a highly dispersed fraction in supersaturated solutions during formation of calcium sulfate precipitates" Kolloid. Zh. 35(4): 781-783 (1973) Abstract	
JDA	38.	Venkatesh "Development of controlled-release SK&F 82526-J buffer bead formulations with tartaric acid as the buffer" Pharm Dev Technol. 3(4):477-485 (1998)	

Examiner /James Anderson/	Date Considered 02/20/2007
---------------------------	----------------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.